Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Cumberland Pharmaceuticals Inc (CPIX) NPV

Sell:$6.10 Buy:$6.24 Change: $0.05 (0.81%)
NASDAQ:1.39%
Market closed |  Prices as at close on 18 June 2019 | Switch to live prices |
Sell:$6.10
Buy:$6.24
Change: $0.05 (0.81%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 18 June 2019 | Switch to live prices |
Sell:$6.10
Buy:$6.24
Change: $0.05 (0.81%)
Market closed |  Prices as at close on 18 June 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company's product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease; Vaprisol (conivaptan) Injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Hepatoren (ifetroban) Injection, and Boxaban (ifetroban) oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease (AERD).

Contact details

Address:
2525 W End Ave Ste 950
NASHVILLE
37203-1608
United States
Telephone:
+1 (615) 2550068
Website:
www.cumberlandpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CPIX
ISIN:
US2307701092
Market cap:
$95.82 million
Shares in issue:
15.54 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • A. Kazimi
    Chairman of the Board, Principal Executive Officer
  • Michael Bonner
    Senior Director Finance and Accounting and Chief Financial Officer
  • Martin Cearnal
    Senior Vice President, Chief Commercial Officer, Director
  • Leo Pavliv
    Senior Vice President - Operations, Chief Development Officer
  • James Herman
    Vice President - National Accounts, Chief Compliance Officer
  • Amy Rock
    Vice President - Regulatory & Scientific Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.